Should SGLT2i be used prior to transcatheter edge‐to‐edge repair for secondary mitral regurgitation?
Open Access
- 27 March 2021
- journal article
- editorial
- Published by Wiley in Clinical Cardiology
- Vol. 44 (5) , 596-598
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection FractionJACC, 2021
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsThe Lancet, 2020
- Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to DateTherapeutics and Clinical Risk Management, 2020
- Treatment of Functional Mitral Regurgitation in Chronic Heart Failure: Can We Get A ‘Proof of Concept’ from the MITRA-FR and COAPT TRIALS?European Journal of Heart Failure, 2019
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial EnergeticsJACC, 2019
- Transcatheter Mitral-Valve Repair in Patients with Heart FailureNew England Journal of Medicine, 2018
- Percutaneous Repair or Medical Treatment for Secondary Mitral RegurgitationNew England Journal of Medicine, 2018